InvestorsHub Logo
Followers 128
Posts 2150
Boards Moderated 1
Alias Born 12/27/2007

Re: None

Friday, 08/12/2016 9:22:24 AM

Friday, August 12, 2016 9:22:24 AM

Post# of 12450

The Company has now Cash untill mid 2018 excluding Upfront Payments from new Partnerships and Product Revenues . Partnerdeal news and Phase 1 Results of their Alzheimer Drug coming within 6 Weeks . Market Cap still way below $50 Million which is still a big Joke .

from yesterdays 2Q Results
http://www.intelgenx.com/investors/press-releases/press-release-details/2016/IntelGenx-Reports-Second-Quarter-2016-Financial-Results-and-Appointment-of-New-Director/default.aspx

Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016

Initiated a phase 1 study of Montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia.IntelGenx expects results from the phase 1 trial to be available in September 2016.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News